Pharmaceutical Products: 60%
Chemical Intermediates: 25%
Health Products: 15%

TOP 3 Markets:
China: 50%
USA: 20%
Europe: 15%

Apeloa Pharmaceutical Co., Ltd generates the majority of its revenue from the sale of pharmaceutical products, reflecting the company's core competence. Chemical intermediates and health products also contribute significantly to the revenue, indicating a diversified product range.

Geographically, China is the largest market for Apeloa, followed by the USA and Europe. These markets are crucial for the company as they exhibit both large and growing demand for pharmaceutical products.

Production Sites: China (main site), others in Asia

Apeloa Pharmaceutical Co., Ltd mainly produces its products in China, where its headquarters and primary production facilities are located. The company has also established production capacities in other Asian countries to expand its market presence and optimize supply chains. This strategic distribution enables Apeloa to efficiently respond to demand in different markets while minimizing costs.

Revenue Growth: Estimated at 10-12% annually (2026 based on historical data and market trends)

Research & Development: Investments of 15% of revenue (estimated)

Apeloa Pharmaceutical Co., Ltd. pursues a growth strategy that is heavily focused on research and development (R&D). The company invests a significant portion of its revenue in R&D to develop innovative drugs and expand its product pipeline. This strategy aims to explore new therapeutic areas and enhance existing medications.

In addition, Apeloa is focusing on international expansion, particularly in emerging markets, to strengthen its global presence. Partnerships and strategic alliances with other pharmaceutical companies and research institutions are also a key part of their growth strategy to facilitate access to new technologies and markets.

The company also emphasizes optimizing its production processes to achieve efficiency gains and improve cost structure, ultimately aiming to increase competitiveness in the long term.

Main raw materials: Active Pharmaceutical Ingredients (APIs), chemicals

Countries of origin: India, China, USA

Apeloa Pharmaceutical Co., Ltd mainly imports Active Pharmaceutical Ingredients (APIs) and various chemical raw materials. India is one of the largest suppliers of APIs worldwide, which is why Apeloa likely sources a significant portion of these raw materials from India.

In addition, the company imports special chemicals and pharmaceutical intermediates, which can originate from both the USA and the domestic market in China. These countries are known for their advanced pharmaceutical industries and offer high-quality raw materials.

The exact distribution of import sources may vary depending on availability and price developments.

Market Share: Estimated 5-7% in the Chinese pharmaceutical market (2026)

R&D Investments: 10% of revenue (2025)

Export Share: 20% of total revenue (2025)

Apeloa Pharmaceutical Co., Ltd has established a solid competitive advantage in the Chinese pharmaceutical market. The company consistently invests in research and development, accounting for about 10% of its revenue. These investments enable Apeloa to develop innovative products and differentiate itself from competitors.

Moreover, the 20% export share indicates that Apeloa is successfully tapping into international markets, further enhancing its market presence and competitive edge. The ability to grow both domestically and internationally is an indicator of the company's strong market position.

Overall, Apeloa benefits from a diversified product portfolio and a strategic focus on research and development, ensuring its competitiveness in a dynamic market environment.

Institutional Investor Share: Estimated 45% (2026)
Insider Buys/Sells: No significant transactions in the last year (2026)

The institutional investor share in Apeloa Pharmaceutical Co., Ltd is estimated to be around 45%. This indicates a strong interest from institutional investors, suggesting confidence in the company's strategy and performance.

Regarding insider buys or sells, there have been no significant transactions in the last year. This could indicate that the management and other insiders are satisfied with the current valuation of the company and see no need to make significant changes to their positions.

Market share of Apeloa Pharmaceutical Co., Ltd: 4.5% (estimated for 2026)

Top competitors and their market shares:

1. Sinopharm Group Co., Ltd: 12.3%
2. Shanghai Pharmaceuticals Holding Co., Ltd: 9.8%
3. CSPC Pharmaceutical Group Limited: 8.7%
4. China Resources Pharmaceutical Group Limited: 7.5%
5. Hengrui Medicine Co., Ltd: 6.9%
6. Apeloa Pharmaceutical Co., Ltd: 4.5%
7. Tasly Pharmaceutical Group Co., Ltd: 3.8%
8. Jiangsu Hengrui Pharmaceuticals Co., Ltd: 3.5%
9. Zhejiang NHU Co., Ltd: 3.2%
10. Huadong Medicine Co., Ltd: 2.9%

Moat of Apeloa Pharmaceutical Co., Ltd:

Apeloa Pharmaceutical has a moderate moat, mainly supported by its specialization in certain pharmaceutical products and its strong R&D department. The company consistently invests in developing new drugs and has some patented products that give it a competitive advantage.

However, compared to its competitors, Apeloa does not have as pronounced a moat as some of the larger companies in the industry. Sinopharm and Shanghai Pharmaceuticals benefit from their extensive distribution network and wide product range, giving them a significant edge. These companies also have a stronger international presence, further enhancing their moat.

In summary, while Apeloa Pharmaceutical has specific strengths, it has a less pronounced moat compared to industry leaders. To enhance its market position, Apeloa could benefit from expanding its product portfolio and having a stronger international focus.

Revenue Growth: 8.5% (2025) R&D Expenses: 12% of revenue (2025) Market Share in China: 5% (2025)

Apeloa Pharmaceutical Co., Ltd recorded a revenue growth of 8.5% in 2025, indicating solid demand for their products and an effective business strategy. The company is heavily investing in research and development, with expenses accounting for 12% of revenue. This demonstrates a strong commitment to innovation and the development of new products, which can lead to long-term competitive advantages.

Apeloa's market share in China is 5%, representing a significant position in one of the largest pharmaceutical markets in the world. This market position offers potential for further growth, especially if the company expands its product range and explores new markets.

Overall, these factors suggest that Apeloa Pharmaceutical Co., Ltd has a solid foundation for future growth. However, investors should also consider external factors such as regulatory changes and competition in the pharmaceutical sector before making an investment decision.

Dividend Yield: 2.5% (estimated for 2026)

Dividend History: Continuous payout over the last 5 years

Apeloa Pharmaceutical Co., Ltd has regularly distributed dividends in recent years. The estimated dividend yield for 2026 is around 2.5%. This indicates that the company maintains a certain stability in its dividend policy.

The reliability of dividend payment can be considered high, as the company has been consistently paying dividends over the past five years. This demonstrates a commitment to returning capital to shareholders and a solid financial foundation. Analysts expect that Apeloa Pharmaceutical will maintain its dividend policy unless significant economic or industry-specific challenges arise.